Sleep Cycle Sees Strong Early Demand for AI Sleep Apnea Risk Tool

Sleep Cycle AB ( (SE:SLEEP) ) has shared an announcement.

Sleep Cycle is deepening its push into medical technology with an AI-powered sleep apnea risk detection tool, leveraging its established audio-based sleep analysis platform to deliver at-home assessments embedded in users’ normal sleep routines. The move positions the Gothenburg-based company to extend beyond consumer sleep tracking into regulated health applications and B2B collaborations with insurers, employers, and digital health platforms.

The company reports more than 150,000 people have already registered interest ahead of the solution’s commercial launch, largely from the U.S. and U.K. and predominantly adults aged 45 and above, underscoring significant unmet demand in a demographic heavily affected by undiagnosed sleep apnea. This early traction supports Sleep Cycle’s commercial planning and partner discussions in a structurally growing global market for sleep apnea diagnostics and at-home testing, estimated at about SEK 10 billion, where scalable digital tools are increasingly sought to manage health risks more proactively.

The most recent analyst rating on (SE:SLEEP) stock is a Hold with a SEK18.00 price target. To see the full list of analyst forecasts on Sleep Cycle AB stock, see the SE:SLEEP Stock Forecast page.

More about Sleep Cycle AB

Sleep Cycle AB is a Sweden-based sleep technology company listed on Nasdaq Stockholm under the ticker SLEEP, specializing in app-based sleep tracking and analysis using patented audio technology and over 3 billion analyzed sleep sessions. The company targets consumers and business partners with personalized sleep insights, in-app services, SDK solutions, and data partnerships aimed at improving sleep health and expanding digital wellness offerings.

Average Trading Volume: 45,546

Technical Sentiment Signal: Sell

Current Market Cap: SEK344.7M

For an in-depth examination of SLEEP stock, go to TipRanks’ Overview page.